Scottish Cancer Registry (SMR06)

Preview of JSON file

[{"id": "", "description": "DIAGNOSIS DETAILS (Tumour Level)", "name": "DIAGNOSIS DETAILS", "dataElementsCount": 23, "dataElements": [{"id": "", "description": "Death certificate initiated indicates that the case has FIRST come to light ONLY as a result of a death, as assessed from the source records available at the time of confirming the registration. However, subsequent evidence may be discovered \u2018out in the field\u2019. Options:\n\nCode \tDescription \n0 \tNo \n1 \tYes", "name": "Death Certificate Initiated", "type": "PrimitiveType"}, {"id": "", "description": "ICDO - International Classification of Diseases for Oncology. Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICD-O morphology code and a fifth digit which denotes behaviour of the tumour.  \nAll registrations with a Scottish incidence date up to and including 31.12.1996 should be classified according to the ICDO classification.   \n5th digit options: \n \nCode \tDescription \n0 \tBenign \n1 \tUncertain whether benign or malignant   \n2 \tCarcinoma in situ \n3 \tMalignant- primary site \n6 \tMalignant- metastatic site or secondary site \n9 \tMalignant- uncertain whether primary or metastatic site", "name": "Tumour Type - ICDO Code", "type": "PrimitiveType"}, {"id": "", "description": "The code identifies the Cancer Information Officer (CIO) who first confirms the registration. This field remains unchanged regardless of any subsequent amendments by other staff. This is automatically allocated by the Socrates system.", "name": "CIO of Registration", "type": "PrimitiveType"}, {"id": "", "description": "Microinvasive is used to describe a degree of invasion which is not associated with any risk of nodal metastasis and is sufficiently small to treat by local or conservative means.  Options:  \n \nCode \tDescription \n0 \tNo \n1 \tYes \n9 \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.2005", "name": "Microinvasive", "type": "PrimitiveType"}, {"id": "", "description": "ICDO(3) - International Classification of Diseases for Oncology (3rd revision). Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICDO(3) morphology code and a fifth digit which denotes behaviour. \n5th digit options: \n \nCode \tDescription \n0 \tBenign \n1 \tUncertain whether benign or malignant \n2 \tCarcinoma in situ \n3 \tMalignant- primary site \n6 \tMalignant- metastatic site or secondary site \n9 \tMalignant- uncertain whether primary or metastatic site \nPlease note there are some differences between ICDO(2) and  ICDO(3) including the change in behaviour of certain tumour types from one classification to the other. This field will be completed for all registrations with a Scottish incidence date from 1.1.2006. Registrations with a Scottish incidence date from 1.1.2012 onwards, will adopt the 2011 updated version of codes for ICDO3.", "name": "Tumour Type - ICDO(3) Code", "type": "PrimitiveType"}, {"id": "", "description": "This field is collected for all registrations with a Scottish incidence date from 1.1.2011.   Options: \nCode \tDescription \n1 \tTertiary 1 \n2 \tTertiary 2 \n3 \tTertiary 3 \n4 \tTertiary 4 \n5 \tTertiary 5 \n9 \tNot Known \n \nThe tertiary component of the Gleason score was previously not recorded but indicates a generally more aggressive pattern of the tumour and in some cases may be preferred as a measure with the Gleason Major to derive a Gleason score. \nTo be completed for all prostate cases with an ICD10 code of C61.", "name": "Gleason Tertiary", "type": "PrimitiveType"}, {"id": "", "description": "Most Valid Basis of diagnosis indicates the method judged to have best provided or validated the diagnosis during the course of the illness.  Options: \nCode \tDescription \n1 \tClinical only \n2 \tClinical investigation (including x-ray, ultrasound, etc.) \n3 \tExploratory surgery/endoscopy/autopsy  (without concurrent or previous histology) \n4 \tSpecific biochemical and/or immunological tests (e.g. Prostate Specific Antigen (PSA) - for prostate cancer or Bence Jones Protein (BJP) - for Myeloma) \n5 \tCytology (including blood film or bone marrow aspirate) \n6 \tHistology of metastasis \n7 \tHistology of primary \n8 \tAutopsy (with concurrent or previous histology) \n9 \tNot Known \n10 \tDeath certificate only   \n \nThe methods of diagnosis are listed in essentially ascending order of validity, microscopic methods having greater validity than non-microscopic methods. \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Most Valid Basis of Diagnosis", "type": "PrimitiveType"}, {"id": "", "description": "This field is collected for all registrations with a Scottish incidence date from 1.1.2011 onwards.   Options:  \n \nCode \tDescription \n1 \tMinor 1 \n2 \tMinor 2 \n3 \tMinor 3 \n4 \tMinor 4 \n5 \tMinor 5 \n9 \tNot Known \n \nPreviously, this was recorded as a combined Gleason score with the Gleason Major component. (See above). These are now recorded separately. \nTo be completed for all prostate cases with an ICD10 code of C61.", "name": "Gleason Minor", "type": "PrimitiveType"}, {"id": "", "description": "Histological Verification is microscopic confirmation of the histological or cytological diagnosis (including examination of peripheral blood film). For post-97 registrations, HV-verified should correspond with Most Valid Basis Of Diagnosis options 5-8.  \nNOTE - CIN 3 should only be registered if the diagnosis is based on histology, not cytology alone.  Options: \n \nCode \tDescription \n1 \tVerified \n2 \tNot verified", "name": "Histological \nVerification", "type": "PrimitiveType"}, {"id": "", "description": "ENCR (European Network of Cancer Registries) incidence date will be recorded from 01.01.2019.   \n \nENCR Incidence Date definition; \n \n\u201cThe date of the first event (7 to choose from outlined below) to occur chronologically should be chosen as ENCR incidence date.  If an event of higher priority occurs within 3 months of the date initially chosen, the date of the higher priority event should take precedence.\u201d \n \nThe date of the first event of the 7 listed to occur chronologically should be chosen as ENCR incidence date. If an event of higher priority occurs within three months of the date initially chosen, the date of the higher priority event should take precedence.", "name": "ENCR Incident Date", "type": "PrimitiveType"}, {"id": "", "description": "ICDO(2) - International Classification of Diseases for Oncology (2nd revision). Similar to ICD10 site code, but there are differences in the site code ranges. ICDO(2) does not include type specific codes such as lymphomas (C82-C85) or Kaposi\u2019s sarcoma (C46), but has the ability to code such neoplasms more precisely to their site of origin. All registrations should now be completed with an ICDO(2) site code, regardless of incidence. This field is collected for all registrations with a Scottish incidence date from 1.1.1997.  With the introduction of ICDO(3), it should be noted that there is no change in the codes for SITE from ICDO(2) to ICDO(3).", "name": "Tumour Site \u2013 ICDO(2) / ICDO(3) Code", "type": "PrimitiveType"}, {"id": "", "description": "This indicates the side or laterality of origin (i.e. left or right) in the case of paired organs.  (e.g. breast, kidney, limb, lung, ovary, testis). Acceptable SIDE is based on the current UKACR table of Laterality. Tumours existing in both sides of a paired organ should be registered twice for Left and Right. The only paired organs to be treated as a single site (bilateral) are tumours of the ovary and Wilms tumour of the kidney or nephroblastoma. (ICDO(3) 8960/3) Options: \nCode \tDescription \n0 \tNot applicable (non paired organs) \n1 \tRight \n2 \tLeft \n3 \tBilateral \n9 \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Side (Laterality)", "type": "PrimitiveType"}, {"id": "", "description": "Method of first detection indicates how the tumour was first detected. \n \nOptions: \nCode \tDescription \n1 \tScreening examination \n2 \tIncidental finding (on examination or at surgery for an unrelated reason) \n3 \tClinical presentation (with relevant symptoms) \n4 \tIncidental finding at autopsy (previously unsuspected) \n5 \tInterval cancer \n8 \tOther \n9 \tNot Known \n \nInterval cancer is an option introduced in the redeveloped SOCRATES in 2006. It describes when a primary tumour with histological confirmation is diagnosed in the interval following a negative screening episode and before the next scheduled screening examination.  The \"interval\" relates to the interval between screenings rather than the interval between separate tumour occurrences. \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Method of First Detection", "type": "PrimitiveType"}, {"id": "", "description": "This field is collected for all registrations with a Scottish incidence date from 1.1.2011 onwards.   Options:  \n \nCode \tDescription \n1 \tMajor 1 \n2 \tMajor 2 \n3 \tMajor 3 \n4 \tMajor 4 \n5 \tMajor 5 \n9 \tNot Known \n \nPreviously, this was recorded as a combined Gleason score with the Gleason Minor component. (See above). These are now recorded separately. \nTo be completed for all prostate cases with an ICD10 code of C61.", "name": "Gleason Major", "type": "PrimitiveType"}, {"id": "", "description": "The date the Cancer Information Officer confirms a registration on the SOCRATES cancer registration database, having passed all validation checks. This is automatically allocated by the Socrates system.", "name": "Date of Registration", "type": "PrimitiveType"}, {"id": "", "description": "Grade or cell type indicates the degree of differentiation of malignant tumours or the T-cell & B-cell designation for lymphomas and leukaemias and is sometimes recorded as the sixth digit of the ICDO morphology code, although this is not recorded on SOCRATES. \n \nBreast options:  \nCode \tDescription \n1 \tGrade 1 / low grade   \n2 \tGrade 2 / intermediate grade   \n3 \tGrade 3 / high grade   \n9 \tNot Known \n \nProstate -\u2018Gleason Score\u2019 Options: 2 -10 or 0 (Not known).  \nUp to Scottish incidence date 31.12. 2010, the Gleason score will be recorded as the sum of the \nGleason Major score and Gleason Minor score. From 1.1.2011 Scottish incidence date onwards, the Grade or Cell type field will contain the Gleason Major, Minor and Tertiary score separately. Options: 1 - 5 or 9 (Not known).  \nTo be completed for all prostate cases with an ICD10 code of C61. \n\nKidney \u2013 \u2018Fuhrman\u2019/ISUP (VANCOUVER) Options: \nCode \tDescription \n1 \tGrade I \n2 \tGrade II \n3 \tGrade III \n4 \tGrade IV \n9 \tNot Known \n \nWHO (Brain and CNS) Options:  \nCode \tDescription \n1 \tGrade I \n2 \tGrade II \n3 \tGrade III \n4 \tGrade IV \n9 \tNot Known \n \n \n \n \nGIST (sarcoma GIST tumours only) Options: \nCode \tDescription \nGX \tGrade cannot be assessed \nG1 \tLow grade; mitotic rate 5/50 per high-power field (HPF) or less \nG2 \tHigh grade; mitotic rate > 5/50 HPF \n \nICD-O/UICC Options:  \n\tCode \tDescription \n\t1 \t(Well) differentiated   \n\t2 \tModerately (well) differentiated \n\t3 \tPoorly differentiated   \n\t4 \tUndifferentiated, anaplastic \n\t5 \tT-Cell (inc. T-precursor)  \n\t6 \tB-Cell (inc. Pre-B, B-precursor) \n\t7 \tNull Cell ( Non T-non B, leukaemias only) \n\t8 \tNatural killer (NK) Cell   \n\t9 \tGrade/Cell type or differentiation not determined, not stated or not applicable. \n\nTo be used for all diagnostic sites other than those above. \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Grade or Cell type", "type": "PrimitiveType"}, {"id": "", "description": "Scottish Incidence date is the date that the cancer in question becomes formally known to NHS \nScotland. Previously known as \u2018date treatment commenced\u2019 and/or \u2018Incidence Date\u2019. Can be termed \n\u201cdate of diagnosis\u201d \n(A) For patients seen as outpatients and/or day cases and/or inpatients (other than long stay or residential), it is the earliest available date from the following: - Date of first consultation as an outpatient.             - Date of first pathology report confirming diagnosis - Date of admission to hospital.                                \n- Date of hospital-initiated treatment \nIf none of the above dates apply or can be established, the date of diagnosis (or best estimate) should be used. \n(B)\tFor long stay or residential patients, or patients receiving care at home, it is the date of diagnosis (or best estimate). \n(C)\tFor death certificate only cases (when follow-up attempts have been unsuccessful), and for cases first diagnosed at autopsy (unsuspected during life), it is the date of death.", "name": "Scottish Incidence Date", "type": "PrimitiveType"}, {"id": "", "description": "ENCR Event type has to be chosen from table below: \n \n\tCode \tDescription \n\t1 \tDate of 1st histological/cytological confirmation \n\t2 \tDate of admission to hospital  \n\t3 \tDate of 1st consultation at outpatient clinic \n\t4 \tDate of diagnosis other than 1, 2, 3 (incl. diagnostic imaging that confirms registerable disease) \n\t5 \tTreatment date \n6 \tDate of Death \n7 \tDate of death - autopsy", "name": "ENCR Event", "type": "PrimitiveType"}, {"id": "", "description": "Indicates the classification system used for grading tumour.  Options: \n \nCode \tDescription \n1 \tGrading for breast cancer (ICD10 C50 and D05). \n2 \tICD-O/UICC \n3 \tGleason Score (Prostate only \u2013 ICD10 C61)   \n4 \tBloom and Richardson (Breast only) *NOW OBSOLETE* \n5 \tFuhrman nuclear grade/ISUP (VANCOUVER) (Renal cell carcinomas of kidney \u2013 ICD10 C64 \n6 \tWHO grade (Brain and CNS only -  ICD10 C70-C72, D32 \u2013 D33, D35.2 \u2013 D35.4, D42 \u2013 D43, D44.3 \u2013 D44.5 \n7 \tGIST only C15*, C16*, C17*, C18*, C20*, C25*, C269, C48.1, C762, C80* and morphology 89363 \n8 \tOther \n9 \tNot determined/not stated/not applicable \n \nFor code 1 note: \nThe Nottingham grading system (previously option 1) and the Bloom and Richardson grading system (previously option 4) have been combined, as one is essentially a modification of the other. The new Grading for breast cancer (option 1) will be used from the introduction in October 2010 of the newly developed Socrates version and should be completed for all cases of breast cancer. Option 4 is now obsolete. All previously registered cases of Bloom and Richardson Grade have been electronically amended to record the new option 1.  \n \nFor code 5 note: \nFuhrman nuclear grade was introduced as an option in Socrates in 2006. Previously, this classification was recorded under [8] Other. ISUP (VANCOUVER) was introduced as an option in Socrates in 2014. \n \nFor code 6 note: \nThis was previously recorded under [8] Other with a note of grade in the Admin screen. To be collected for records from 1.1.2006 Scottish incidence onwards. \nFor code 7 note: \nThis was introduced for 2016 registrations. \n For most other cancers, the ICD-O/UICC grading system is used. If the grade of differentiation is explicitly enumerated in the pathology report it should be recorded as such. If it is not explicitly stated, it may be derived from the text of the pathology report according to the definition options stated for Grade below. Grade is recorded every time this information is available except when T or B cell origin is provided for lymphomas & leukaemias. In this event, the T or B - cell origin has priority and also has options stated in Grade definition below.  \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Grade Classification Used", "type": "PrimitiveType"}, {"id": "", "description": "ICDO(2) - International Classification of Diseases for Oncology (2nd revision). Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICDO(2) morphology code and a fifth digit which denotes behaviour. All registrations with a Scottish incidence date from 1.1.1997 to 31.12.2005 should now be completed with an ICD(O)2 morphology code. There are some differences between ICDO and ICDO(2) including the change in behaviour of certain tumour types from one classification to the other.", "name": "Tumour Type - ICDO(2) Code", "type": "PrimitiveType"}, {"id": "", "description": "ICD9 \u2013 International Classification of Diseases (9th revision). All registrations with a Scottish incidence date up to and including 31.12.1996 should be classified according to the ICD9 classification. This field should also be completed for all \u201cDeath Certificate Only\u201d (DCO) cases with a Scottish incidence date up to and including 31.12.1999.", "name": "Diagnostic code - ICD9 Code", "type": "PrimitiveType"}, {"id": "", "description": "This indicates that the case has been registered from the death certificate only, since no other evidence of the tumour can be found. i.e. No information from medical records, and no source records other than the death record. Options:  \n \nCode \tDescription \n0 \tNo \n1 \tYes", "name": "Death Certificate Only", "type": "PrimitiveType"}, {"id": "", "description": "ICDO(2) - International Classification of Diseases for Oncology (2nd revision). Similar to ICD10 site code, but there are differences in the site code ranges. ICDO(2) does not include type specific codes such as lymphomas (C82-C85) or Kaposi\u2019s sarcoma (C46), but has the ability to code such neoplasms more precisely to their site of origin. All registrations should now be completed with an ICDO(2) site code, regardless of incidence. This field is collected for all registrations with a Scottish incidence date from 1.1.1997.  ICD10 \u2013 International Classification of Diseases (10th revision). All registrations with a Scottish incidence date from 1.1.1997 onwards should be completed with an ICD10 (version 3) site code. Registrations with a Scottish incidence date from 1.1.2014 will be taking into account the modified version of ICD10 (version 4)  and using these codes in line with other NHS Scotland organisations for local and national return purposes.", "name": "Diagnostic code - ICD10", "type": "PrimitiveType"}]}, {"id": "", "description": "HISTORICAL DATA (1950-1996 registrations only)", "name": "HISTORICAL DATA", "dataElementsCount": 20, "dataElements": [{"id": "", "description": "Indicates if a GRO(S) match has been made to update record", "name": "Old GRO(S) Flag", "type": "PrimitiveType"}, {"id": "", "description": "Occupation of patient at time of registration. This is a 3 digit code according to OPCS classifications. Range: 001-350, 666 &777. Only collected on pre-SOCRATES data.", "name": "Occupation", "type": "PrimitiveType"}, {"id": "", "description": "STATISTICAL DATA (used for all registrations)", "name": "Output Area 2001", "type": "PrimitiveType"}, {"id": "", "description": "Social Class - Derived from the occupation code of the patient on the Scottish incidence date", "name": "Social Class", "type": "PrimitiveType"}, {"id": "", "description": "As above", "name": "HB Residence number", "type": "PrimitiveType"}, {"id": "", "description": "Local government district (1 \u2013 68)", "name": "Grid Ref Northing", "type": "PrimitiveType"}, {"id": "", "description": "ED Grid Reference - Derived from the Enumeration District of the patient on the Scottish incidence date. The northing with the origin based in the Scilly isles.", "name": "Urban / Rural", "type": "PrimitiveType"}, {"id": "", "description": "Sequential number allocated by each regional registry computer system (not unique)", "name": "Old Can Reg No.", "type": "PrimitiveType"}, {"id": "", "description": "NOTE: postcode-derived variables are of uncertain reliability and are due to be further developed.", "name": "Output Area 1991", "type": "PrimitiveType"}, {"id": "", "description": "Batch numbers allocated to data prior to DTC 1997", "name": "Old Batch Number", "type": "PrimitiveType"}, {"id": "", "description": "A letter (cypher) relating to the locale, of the resident population, represented as one of 15 Scottish Health Board Areas", "name": "Local Govt District", "type": "PrimitiveType"}, {"id": "", "description": "Institution code of institution of registration - Mandatory for Pre-97 tumours.", "name": "Old Hospital code", "type": "PrimitiveType"}, {"id": "", "description": "Output areas are the smallest geographical unit for which Census data are available  There were 42,604 output areas at the 2001 Census with a mean population size of 119 people. The smallest output area represented 50 people and the largest 2,357 people. This wide variation was due to a few large output areas with populations in communal establishments.  However, the population sizes have become increasingly variable in the years since the 2001 Census due to population migration.", "name": "HB Residence cypher", "type": "PrimitiveType"}, {"id": "", "description": "ED Grid Reference - Derived from the Enumeration District of the patient on the Scottish incidence date. The easting with the origin based in the Scilly isles.", "name": "Local Council Area", "type": "PrimitiveType"}, {"id": "", "description": "Urban/Rural Status Indicator \u2013 Derived from the Postcode of the patient on the Scottish incidence date", "name": "Constituency", "type": "PrimitiveType"}, {"id": "", "description": "This uniquely identifies which one of the five Scottish regional registries has made the registration. Mandatory for Pre-97 tumours. \n \nCode \tDescription \n0 \tNorth (Inverness) \n2 \tNorth-East (Aberdeen) \n3 \tEast (Dundee) \n4 \tSouth-East (Edinburgh) \n5 \tWest (Glasgow)", "name": "Old Registry", "type": "PrimitiveType"}, {"id": "", "description": "Other case ref. numbers used (pre 1997)", "name": "Old Alt Case No.", "type": "PrimitiveType"}, {"id": "", "description": "The local government council area, as defined by the reorganisation of 1 April 1996, where the patient normally resides.    This information is derived directly from the patient's postcode of residence.", "name": "Part", "type": "PrimitiveType"}, {"id": "", "description": "Number designated to HB of Residence (1 \u2013 15)", "name": "Grid Ref Easting", "type": "PrimitiveType"}, {"id": "", "description": "Parish area - Derived from the postcode of the patient on the Scottish incidence date", "name": "Parish code", "type": "PrimitiveType"}]}, {"id": "", "description": "IDENTIFICATION AT DIAGNOSIS (Tumour Level)", "name": "IDENTIFICATION AT DIAGNOSIS", "dataElementsCount": 16, "dataElements": [{"id": "", "description": "See Person screen definitions.", "name": "Date of Death", "type": "PrimitiveType"}, {"id": "", "description": "A unique number which will enable the unequivocal identification of individual cancer patients. It is a sequential number allocated by the computer system SOCRATES (For historical data it will result from person-based linkage).", "name": "Person Identifier", "type": "PrimitiveType"}, {"id": "", "description": "National Health Service (NHS) number is the identifier allocated to an individual to enable unique identification within the UK for NHS health care purposes. (Part of COPPISH SMR patient ID section).", "name": "NHS Number", "type": "PrimitiveType"}, {"id": "", "description": "Hospital Patient Health Record Identifier was previously Case Reference Number and refers to the Case Ref. No. from the institution of diagnosis. Part of COPPISH SMR patient ID section & is combined with Health Records System Identifier to make up the \u2018Patient Record Identifier\u2019 which is used to uniquely identify a patient within a health register or health records system such as PAS.", "name": "Case Reference (Hospital Record ID)", "type": "PrimitiveType"}, {"id": "", "description": "Practice code of patient\u2019s GP (Part of COPPISH SMR patient ID section). Each GP practice in Scotland is identified by a unique code. The practice code is a four digit code plus a check digit with ranges of code allocated to each Health Board.  This field is collected for all registrations with a Scottish incidence date from 1.1.1997", "name": "GP Practice Code", "type": "PrimitiveType"}, {"id": "", "description": "Usual full address of residence of the person on the Scottish incidence date i.e. the residence at which the person resides for the majority of time. Must be within Scottish boundaries.  This field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Address at Diagnosis", "type": "PrimitiveType"}, {"id": "", "description": "Forenames or initials of the patient on the Scottish incidence date. May include a hyphen or an apostrophe, e.g. Mary-Jane or T\u2019Pau. Each forename/initial to be separated by a space.", "name": "Forenames at Diagnosis", "type": "PrimitiveType"}, {"id": "", "description": "See Person screen definitions.", "name": "Ethnic Group", "type": "PrimitiveType"}, {"id": "", "description": "Postcode for the usual place of residence of the person on the Scottish incidence date. Must be Scottish postcode according to ISD postcode reference files.", "name": "Postcode at Diagnosis", "type": "PrimitiveType"}, {"id": "", "description": "Marital Status has been recorded since registration began, the options originally part of the COPPISH SMR patient ID section. Options:\nOption 1 \nDescription \nNever married (single) \nMarried (includes separated) \nWidowed \nOther (includes divorced) \nNot Known \n \nTo take account of the Scottish Government Core Survey Question relating to \u201cLegal Marital Status\u201d, this field has been reviewed.  \nFrom 1.4.2012 to 31.3.2013 Scottish incidence date, registrations may be recorded with Option 1 or Option 2: \n \nOption 2 \nDescription \nNever married nor registered civil partnership   \nMarried  \nRegistered civil partnership \nSeparated, but still married   \nSeparated, but still in civil partnership   \nDivorced \nDissolved civil partnership   \nWidowed \nSurviving civil partner   \nOther \nNot Known \n \nFrom 1.4.2013 Scottish incidence, all registrations must use the new coding option.", "name": "Marital Status", "type": "PrimitiveType"}, {"id": "", "description": "See Person screen definitions.", "name": "Date of Birth", "type": "PrimitiveType"}, {"id": "", "description": "The Community Health Index (CHI) is a population register which is used for health care purposes. The CHI number uniquely identifies a person on the index. Prior to January 1997, there were 8 indexes, each", "name": "CHI Number", "type": "PrimitiveType"}, {"id": "", "description": "All surnames by which this person has been known. This includes maiden names, aliases or differences in spelling. The Cancer Information Officer (CIO) cannot amend this field.", "name": "All Surnames", "type": "PrimitiveType"}, {"id": "", "description": "See Person screen definitions.", "name": "Sex (Gender)", "type": "PrimitiveType"}, {"id": "", "description": "Computer generated number given to all new provisional registrations & pre-97 registrations. The confirmed registration will retain this number which uniquely and permanently identifies each tumour registration. Note this is different from the person ID number.", "name": "Record Number", "type": "PrimitiveType"}, {"id": "", "description": "Surname of the patient on the Scottish incidence date. May include a hyphen or an apostrophe e.g. Wilmot-Brown or O\u2019Brien.", "name": "Surname at Diagnosis", "type": "PrimitiveType"}]}, {"id": "", "description": "INITIAL TREATMENT (TUMOUR LEVEL)", "name": "INITIAL TREATMENT", "dataElementsCount": 32, "dataElements": [{"id": "", "description": "Date of first Hormone Therapy DD-MMM-YYYY (if applicable)", "name": "Date of First \nHormone Therapy", "type": "PrimitiveType"}, {"id": "", "description": "Institution code/practice code of Hospital/GP practice initiating Hormone Therapy (if applicable)", "name": "Hospital/GP \nPractice of First \nHormone \nTherapy", "type": "PrimitiveType"}, {"id": "", "description": "Institution code/practice code of Hospital/GP practice where a surgical treatment was first carried out (if applicable)", "name": "Hospital/GP \nPractice of First Radical Surgery", "type": "PrimitiveType"}, {"id": "", "description": "Institution code/practice code of Hospital/GP practice of first Chemotherapy (if applicable)", "name": "Hospital/GP \nPractice of First Chemotherapy", "type": "PrimitiveType"}, {"id": "", "description": "Indicates if patient has had Hormone treatment. Hormone therapy is the use of hormones to treat cancer.  Hormones are 'chemical messengers' released by the organs and dispersed by the blood to produce effects on target organs e.g. oestrogens. Most likely to apply to Breast, Prostate, Endometrial (uterus) and to a lesser extent, hypernephroma of kidney. Options: \n \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Treated with hormone therapy", "type": "PrimitiveType"}, {"id": "", "description": "Institution code of Hospital where Radiotherapy was first carried out (if applicable)", "name": "Hospital/GP \nPractice of First Radiotherapy", "type": "PrimitiveType"}, {"id": "", "description": "Other Therapy. Options:  \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Treated with other therapy", "type": "PrimitiveType"}, {"id": "", "description": "Indicates if patient has been treated with radiotherapy. Radiotherapy is either external beam, or the radioactive source can be introduced directly into the patient\u2019s body. Radiotherapy may be used for: curative treatment e.g. early seminomas, palliative treatment to contain the tumour & control symptoms e.g. metastatic breast cancer, in combination with other curative treatments e.g. for tumours of the cervix, and to sites other than the primary or metastases e.g. organ ablation or prophylaxis.  \nOptions:  \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Treated with Radiotherapy", "type": "PrimitiveType"}, {"id": "", "description": "Institution code/practice code of Hospital/GP practice where a surgical treatment was first carried out (if applicable)", "name": "Hospital/GP \nPractice of First \n(Palliative) Surgery", "type": "PrimitiveType"}, {"id": "", "description": "Type of radiotherapy administered collected from 01.01.2016. Options: \nCode \tDescription \n1 \tBrachytherapy \n2 \tExternal beam/Teletherapy \n3 \tProton beam therapy \n\t4 \t \tRadioisotope therapy \n9 \tNot Known", "name": "Type of radiotherapy", "type": "PrimitiveType"}, {"id": "", "description": "Institution code/practice code of Hospital/GP practice initiating Hormone Therapy (if applicable)", "name": "Hospital/GP Practice  \nof First \nBiological/Immun otherapy", "type": "PrimitiveType"}, {"id": "", "description": "Formerly Treatment Protocol Used This indicates whether the patient has been recruited into a specific clinical trial. Only use the Not Known option if you feel you do not have an adequate set of medical records on which to base your assessment.  Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n9 \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Entered into \nClinical Trial", "type": "PrimitiveType"}, {"id": "", "description": "Date of first radical surgical treatment DD-MMM-YYYY (if applicable)", "name": "Date of First \n(Palliative) Surgery", "type": "PrimitiveType"}, {"id": "", "description": "Date of first radical surgical treatment DD-MMM-YYYY (if applicable)", "name": "Date of First Radical Surgery", "type": "PrimitiveType"}, {"id": "", "description": "Date of first Chemotherapy DD-MMM-YYYY (if applicable)", "name": "Date of First Chemotherapy", "type": "PrimitiveType"}, {"id": "", "description": "Palliative Surgery -there are 4 options for this treatment field:  \nCode \tDescription \n0 \tNo -  no palliative surgery  \n1 \tYes \u2013 to relieve the effects of the tumour but not to remove the tumour e.g. stent/shunt \n7 \tPlanned \u2013 palliative surgery is planned at a later date \n\t9 \t \tNot Known - there are no indications of any past or planned palliative surgical procedures relating to the neoplasm concerned \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.2016", "name": "Treated with \nPalliative Surgery", "type": "PrimitiveType"}, {"id": "", "description": "Date of first Hormone Therapy DD-MMM-YYYY (if applicable)", "name": "Date of First \nBiological/Immun otherapy", "type": "PrimitiveType"}, {"id": "", "description": "Referred to a Clinical Oncologist (Radiotherapist) or Medical Oncologist.  Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned to refer \n\t9 \t \tNot Known \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Referred to Oncologist", "type": "PrimitiveType"}, {"id": "", "description": "Hospital of diagnosis denotes the location (institution) code of the hospital in which the diagnosis was first made. This may also be a GP surgery code if an initial biopsy was taken by a GP. \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997. For registrations with a Scottish incidence date up to 31.12.1996, see Old Hosp Code field on Stats screen.", "name": "Hospital / GP of diagnosis", "type": "PrimitiveType"}, {"id": "", "description": "Indicates the type of Other Therapy treatment carried out. Options: \nCode \tDescription \n1 \tAnagrelide \n2 \tAnti-Helicobacter/H.pylori  treatment/eradication therapy  \n3 \tBisphosphonate \n\t4 \t \tBotox injection \n5 \tCorticosteroids \n6 \tDopamine agonist therapy \n7 \tHelmet/Electric Helmet \n8 \tHyperbaric oxygen therapy \n9 \tSupportive Care/Best Supportive Care \n10 \tVenesection   \n11 \tNo longer in use (Watchful Wait - See option 13)  \n12 \tEmbolisation \n13 \tActive Surveillance/Watchful Wait \n14 \tNot Known \n15 \tPhotopheresis  \n \nThis field was previously text only and was collected for all registrations with a Scottish incidence date from 1.1.1997. \nThis field changed to a dropdown option for registrations from 1.1.2016", "name": "Type of other therapy", "type": "PrimitiveType"}, {"id": "", "description": "Institution code/practice code of Hospital/GP surgery where Other Therapy was first carried out (if applicable)", "name": "Hospital/GP \nPractice of Other Therapy", "type": "PrimitiveType"}, {"id": "", "description": "This is the reason why no treatment has taken place. It applies to all registerable cancers with a Scottish incidence date from 1.1.2017. This is only to be completed if no treatment has taken place.  \n \n \nOptions: \n0 \tDied before treatment was given \n1 \tRefused treatment \n2 \tAsymptomatic \n3 \tDeath Certificate only \n4 \tPost-mortem only \n5 \tUnfit to treat: significant co-morbidity and/or advanced cancer \n6 \tNo record of treatment \n7 \tOther \n8 \tUnknown primary site \n9 \tNo active treatment available \n10 \tNot Known", "name": "No Treatment Reason", "type": "PrimitiveType"}, {"id": "", "description": "Radiotherapy treatment to Metastases. Options:  \nCode \tDescription \n0 \tNo \n1 \tYes \n\t9 \t \tNot Known", "name": "Radiotherapy to \nMetastases", "type": "PrimitiveType"}, {"id": "", "description": "Radiotherapy treatment to Other (such as organ ablation or prophylaxis). Options:  \nCode \tDescription \n0 \tNo \n1 \tYes \n\t9 \t \tNot Known", "name": "Radiotherapy Other", "type": "PrimitiveType"}, {"id": "", "description": "Radiotherapy treatment to Primary site. Options: \nCode \tDescription \n0 \tNo \n1 \tYes \n\t9 \t \tNot Known", "name": "Radiotherapy to \nPrimary", "type": "PrimitiveType"}, {"id": "", "description": "Indicates if patient has had Systemic chemotherapy treatment. \nChemotherapy literally means treatment with drugs but is conventionally used to describe the use of chemical agents to treat cancer. These agents may be used alone, or in conjunction with surgery and/or radiotherapy. Options:  \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Treated with Chemotherapy", "type": "PrimitiveType"}, {"id": "", "description": "Intent is most likely to be curative in early stage of disease e.g. microinvasive, or non invasive, in situ disease, T1 or T2  N0  M0 , node negative breast cancer, Dukes\u2019 A colorectal cancer, FIGO I cervical cancer. Intent unlikely to be curative in advanced disease e.g. M1 breast cancer, Dukes\u2019 D, FIGO IV.  \n \nOptions:  \nCode \tDescription \n1 \tCurative intent \n2 \tNon-curative intent (Palliative) \n9 \tNot Known \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997.", "name": "Therapy \nObjectives", "type": "PrimitiveType"}, {"id": "", "description": "Date of first Other Therapy DD-MMM-YYYY (if applicable)", "name": "Date of First Other Therapy", "type": "PrimitiveType"}, {"id": "", "description": "Surgery -there are 4 options for this treatment field:  \nCode \tDescription \n0 \tNo -  no surgery OR exploratory surgery only with or without diagnostic biopsy [e.g. diagnostic laparotomy with or without incisional biopsy (\u2018open and close\u2019), needle biopsy, and diagnostic endoscopy with or without incisional biopsy \n1 \tYes - partial or total resection of primary and/or metastases (including endoscopic resection or biopsy where there is intent to remove all or bulk of macroscopic neoplastic tissue, e.g., excision biopsy or cone biopsy). Surgery should also include palliative procedures e.g. to bypass obstructive lesions or surgical procedures intended to manipulate hormone levels e.g. by the removal of ovaries or testicles \n7 \tPlanned - surgery is planned at a later date \n\t9 \t \tNot Known - there are no indications of any past or planned surgical procedures relating to the neoplasm concerned \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997 - 31.12.2015 incidence \n.", "name": "Treated with Surgery", "type": "PrimitiveType"}, {"id": "", "description": "Radical Surgery -there are 4 options for this treatment field:  \nCode \tDescription \n0 \tNo -  no radical surgery  \n1 \tYes \u2013 removal, part removal or destruction of the primary tumour e.g. excision, resection or laser treatment. It may also include resection of metastasis \n7 \tPlanned \u2013 radical surgery is planned at a later date \n\t9 \t \tNot Known - there are no indications of any past or planned radical surgical procedures relating to the neoplasm concerned \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.2016 \n.", "name": "Treated with \nRadical Surgery", "type": "PrimitiveType"}, {"id": "", "description": "Date of first Radiotherapy treatment DD-MMM-YYYY (if applicable)", "name": "Date of First Radiotherapy", "type": "PrimitiveType"}, {"id": "", "description": "Indicates if patient has had Biological/Immunotherapy. Biological therapies are treatments that act on processes in cells. They may: stop cancer cells from dividing and growing; seek out cancer cells and kill them; encourage the immune system to attack cancer cells. There are many different types of biological therapies including immunotherapy. Options: \n \nCode \tDescription \n0 \tNo \n1 \tYes \n7 \tPlanned \n\t9 \t \tNot Known \n \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997", "name": "Treated with Biological/Immun otherapy", "type": "PrimitiveType"}]}, {"id": "", "description": "OTHER CONTRIBUTING FACTORS (TUMOUR LEVEL)", "name": "OTHER CONTRIBUTING FACTORS", "dataElementsCount": 15, "dataElements": [{"id": "", "description": "Pathological nodal status -Indicates if the regional lymph nodes were examined. Associated with invasive breast cancer only. Options: \nCode \tDescription \n0 \tNo \n1 \tYes, a sample   \n2 \tYes, axillary node clearance   \n9 \tNot Known \n \nThis field is collected for all malignant tumours of the breast (ICD10 C50*) with a Scottish incidence \ndate from 1.1.1997 to 31.12.2012", "name": "Nodes \nExamined \n(Breast)", "type": "PrimitiveType"}, {"id": "", "description": "Pathological nodal status -Indicates how many of the regional lymph nodes were positive/involved - Options: 0-99 or NK - not known\nRecoded for invasive breast only from 1.1.1997 and for invasive head and neck, colorectal, lung, melanoma or breast from 1.1.2013", "name": "Number Positive/Total number involved/Positive (head and neck, colorectal, lung, melanoma or breast)", "type": "PrimitiveType"}, {"id": "", "description": "Pathological nodal status - Indicates how many regional lymph nodes were examined. Options: 0-99 or NK - not known \nRecoded for invasive breast only from 1.1.1997 and for invasive head and neck, colorectal, lung, melanoma or breast from 1.1.2013", "name": "Number examined/Total number examined (head and neck, colorectal, lung, melanoma or breast)", "type": "PrimitiveType"}, {"id": "", "description": "Breslow thickness (in mm, to 2 decimal places or 99.99 (Not known) will be recorded for all cutaneous melanomas (C43*) with a Scottish incidence date from 1.1.2005.", "name": "Breslow thickness size (mm)", "type": "PrimitiveType"}, {"id": "", "description": "Performance status is an overall assessment of the functional/physical performance of the patient. This is a five point scale in which \u20180\u2019 denotes normal activity and \u20184\u2019 a patient who is 100% bed ridden. This item may occur more than once throughout a patient\u2019s record however, the performance status to be recorded is that closest to Scottish incidence date but prior to treatment. If the performance status falls between two scores then the worst performance status should be taken. This field cannot be derived. This field applies to all registerable invasive cancers C000 \u2013 C97X (excluding non melanoma skin C44) and brain cancers D180, D32*, D33*, D352, D353, D354 with a Scottish incidence date from 1.1.2017.  \n \n    \nOptions: \n\tCode  \tValue  \n\t0  \tFully active, able to carry on all pre-disease performance without restriction  \n\t1  \tRestricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light housework, office work  \n\t2  \tAmbulatory and capable of self care but unable to carry out any work activities: up and about more than 50% of waking hours  \n\t3  \tCapable of only limited self care, confined to bed or chair more than 50% of waking hours  \n\t4  \tCompletely disabled, cannot carry on any self care, totally confined to bed or chair  \n\t9  \tNot recorded", "name": "Performance Status", "type": "PrimitiveType"}, {"id": "", "description": "Oestrogen Receptor Status (or ER status) should be available for breast cases (ICD10 C50 or D05) diagnosed histologically. i.e. confirmed from biopsy, surgical excision or histology of nodes or metastases. Receptor status tests are usually performed on the biopsy specimen and generally issued as a supplementary report after the initial reporting of the biopsy.  \n \nRecord status regardless of any qualifying statements e.g. weakly positive.  \n \nOptions: \nCode \tDescription \n0 \tNegative \n1 \tPositive \n9 \tNot Known \n \nThere are several different scoring systems but the recommended and usual method for both ER and PR testing is the Quick (Allred) score.  \nAllred score: The scores are summed to give a maximum of 8.  Generally reports will state results of ER/PR status as positive or negative for example - \u201cER status: positive 5/8\u201d but some may only provide scores which can be referenced to known positive and negative ranges.  \nA score of 0-1 indicates negative result \nA score of 2\u20133 positive (weak) \nA score of 4\u20136 positive (moderate) \nA score of 7\u20138 positive (strong) \n \nER status may also be recorded as a value from which the status can be derived as shown below: \n \nMethod (assay)                            ER positive                                           ER negative \nDCC                               > or = 20 fmols ER/mg protein                 < 20 fmols ER/mg protein EIA                                 > or = 20 fmols ER/mg protein                 < 20 fmols ER/mg protein \nERICA                            > or = 10% positive staining                     < 10% positive staining \n \nThis field is collected for all registrations of malignant breast tumours (C50) with a Scottish incidence date from 1.1.1997 and additionally for all in situ breast tumours with a Scottish incidence date from 1.1.2009. \n \nNote: This field was moved from the Diagnosis screen in Socrates to the Stage screen in October 2010.", "name": "Oestrogen \nReceptor Status (Breast only)", "type": "PrimitiveType"}, {"id": "", "description": "Progesterone Receptor Status (PR or PgR status) should be available for all breast cases (ICD10 C50 or D05) diagnosed histologically. i.e. confirmed from biopsy, surgical excision or histology of nodes or metastases. Receptor status tests are usually performed on the biopsy specimen and generally issued as a supplementary report after the initial reporting of the biopsy. See method of testing as in Oestrogen Receptor Status. Options: \nCode \tDescription \n0 \tNegative \n1 \tPositive \n9 \tNot Known \n \nIf positive (PgR+ or PR+), the cancer should respond well to hormone suppression treatments. If the score is negative (PgR- or PR-), then the tumour will not be driven by progesterone, and HER2 status may well be sought to determine the most effective treatment.  \n \nThis field is collected for all registrations of malignant or in situ breast tumours (C50 or D05) with a Scottish incidence date from 1.1.2009.", "name": "Progesterone \nReceptor Status (Breast  only)", "type": "PrimitiveType"}, {"id": "", "description": "Pathological nodal status -Indicates if any of the regional lymph nodes were positive/involved  Options:  \nCode \tDescription \n0 \tNo \n1 \tYes \n9 \tNot Known \n \nThis field is collected for invasive breast only from 1.1.1997 and for invasive head and neck, colorectal, lung, melanoma or breast from 1.1.2013", "name": "Positive \nNodes/Nodes involved (head and neck, colorectal, lung, \nmelanoma or breast)", "type": "PrimitiveType"}, {"id": "", "description": "Pathological nodal status -Indicates what regional lymph nodes were examined. Associated with invasive head and neck, colorectal, lung, melanoma or breast cancer. Options:  \nCode \tDescription \n0 \tNo regional lymph nodes removed or aspirated   \n1 \tAspiration or biopsy of regional lymph node \n2 \tSentinel lymph node biopsy \n3 \tRegional lymph node dissection \n9 \tNot Known \n \nThis field is collected for all malignant tumours (ICD10 C00# - C14# or C18# - C21# or C30# - C34# or C43# or C50# or C760 with a Scottish incidence date from 1.1.2013", "name": "Regional Lymph nodes assessment", "type": "PrimitiveType"}, {"id": "", "description": "There are two tests available to measure over-expression of HER2 receptors in a tumour cell.  \n \na)\tImmunochemistry HER2 receptor test (IHC) shows how much of the HER2 protein is present in a tumour cell. \nb)\tFluorescence in-situ hybridisation (FISH).If the HER2 test results are borderline this additional more accurate test, will be carried out to confirm a positive or negative result.   \n \nOptions: \nCode \tDescription \n0 \tNegative \n1 \tPositive \n9 \tNot Known \n This field is collected for all registrations of malignant or in situ breast tumours (C50* or D05*) with a Scottish incidence date from 1.1.2009", "name": "HER2 status \n(Breast  only)", "type": "PrimitiveType"}, {"id": "", "description": "The PSA test is a blood test that can help diagnose prostate problems, including prostate cancer. It measures the amount of prostate specific antigen in blood. It is normal to have a small amount of PSA in the blood but a raised PSA level may suggest a prostate problem.  \n \nThis field applies to prostate cancer only (C61X) with a Scottish incidence date from 1.1.2017. The PSA recorded should be that measured on the date of diagnosis and prior to treatment. If there is no PSA at the time of diagnosis and treatment has commenced take the PSA level prior to referral, this may be taken by the GP.  \n \nThis is a numeric value between 0.1 \u2013 9999999.9 and not known set to 0. This field cannot be derived.", "name": "PSA Level", "type": "PrimitiveType"}, {"id": "", "description": "This denotes the nadir levels as obtained after orchiectomy. This applies to testicular cancers only (C62#) with a Scottish incidence date from 1.1.2017. This field cannot be derived. \n \nOptions: \nS0 \tSerum marker study levels within reference range \nS1 \tLDH <1.5 * N and hCG <5,000(mIU/ml) and AFP < 1000 (ng/ml) \nS2 \tLDH 1.5-10* N or hCG 5,000 \u2013 50,000 (mIU/ml) or AFP 1,000 -10,000 (ng/ml) \nS3 \tLDH >10 * N or hCG >50,000(mIU/ml) or AFP >10,000 (ng/ml) \nX \tNot known \n \nThis can be used in conjunction with TNM staging to derive Testicular Stage.", "name": "Serum Marker", "type": "PrimitiveType"}, {"id": "", "description": "Pathological tumour size is the maximum diameter in mm of the invasive component of the tumour in the fresh or fixed state on the histological preparation.  If the two measurements are discrepant then that obtained from the histological (fixed) section(s) should be recorded. The tumour (not the excised specimen) with the greatest diameter should be used. Option range: 000-999 or NK - not known. This field is collected for all malignant tumours of the breast (ICD10 C50*) with a Scottish incidence date from 1.1.1997 and all malignant tumours of testis (ICD10 C62*) from 1.1.2015", "name": "Pathological Tumour Size   (mm)", "type": "PrimitiveType"}, {"id": "", "description": "Clinical tumour size is the maximum diameter in mm of the invasive component of the tumour, or where multiple tumours exist, the maximum diameter in mm of the largest tumour. Option range: 000-999 or NK - not known\nThis field is collected for all malignant hepatocellular tumours of the liver (ICD10 C220) with a Scottish incidence date from 1.1.2014", "name": "Clinical Tumour Size (mm)", "type": "PrimitiveType"}, {"id": "", "description": "Clarks level is a measure of the depth of invasion into the skin and will be recorded for all cutaneous melanomas (C43*) with a Scottish incidence date from 1.1.2005.  Clarks level options: \n \nCode \tDescription \nI \tClarks I \nII \tClarks II \nIII \tClarks III \nIV \tClarks IV \nV \tClarks V \n9 \tNot Known", "name": "Clarks level", "type": "PrimitiveType"}]}, {"id": "", "description": "PERSON RECORD (Person Level)", "name": "PERSON RECORD", "dataElementsCount": 21, "dataElements": [{"id": "", "description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x8", "name": "Cause of Death 3", "type": "PrimitiveType"}, {"id": "", "description": "Patient\u2019s full date of birth only. The date of birth at person & tumour level may not be the same. Therefore this field is used for the DOB confirmed to be correct. i.e. the latest used or most commonly used if it is a valid date. The main format inclusive of century is DD-MMM-YYYY e.g. 9th Feb 42 is 09-FEB-1942 this is then saved onto the main oracle table as YYYYMMDD 19420242.", "name": "Date of Birth  (P_DATE_OF_BIRTH)", "type": "PrimitiveType"}, {"id": "", "description": "This field is collected for all registrations with a Scottish incidence date from 1.1.1997  These are used by NHS Scotland organisations for local and national return purposes. \nIt describes the patient\u2019s perception of their Ethnic Group. For patients with more than one registration, the Ethnic Group will be updated to reflect the most recent date option. \nOriginally these were based on the UK Dept. Of Health recommendations (Part of COPPISH SMR patient ID section)   \n-  From 1.1.1997 to 30.9.2005 Scottish incidence Ethnic Group 1 options:  \n \nEthnic Group 1 \nCode \tDescription \n00 \tWhite \n01 \tBlack Caribbean \n02 \tBlack African \n03 \tBlack Other \n04 \tIndian \n05 \tPakistani \n06 \tBangladeshi \n07 \tChinese \n08 \tOther Ethnic Group \n09 \tNot Known \n10 \tRefused \nThe following codes were created to reflect the Scottish Census 2001 categories and were used for a short time in conjunction with the old codes. \n-\tFrom 1.10.2005 to 31.3.2006 Scottish incidence. Ethnic Group 1 options OR Ethnic Group 2 options:  \n \nEthnic Group 2 \nCode \tDescription \n1A \tWhite-Scottish \n1B \tWhite-other British \n1C \tWhite-Irish \n1D \tAny other white background \n2A \tAny mixed background \n3A \tIndian \n3B \tPakistani \n3C \tBangladeshi \n3D \tChinese \n3E \tAny other Asian background \n4A \tCaribbean \n4B \tAfrican \n4C \tAny other black background \n5A \tAny other ethnic background \n97 \tRefused/not provided by the patient \n99 \tNot known \n \n-\tFrom 1.4.2006 to 31.3.2010 Scottish incidence Ethnic Group 2 options only \n \n-\tFrom 1.4.2010 to 30.9.2010 Scottish incidence  Ethnic Group 2 options OR Ethnic Group 3 options:  \nEthnic Group 3 \nCode \tDescription \n1A \tWhite-Scottish \n1E \tWhite-English \n1F \tWhite - Welsh \n1G \tWhite-Northern Irish \n1H \tWhite British \n1J \tWhite-Irish \n1K \tGypsy/Traveler \nIL \tPolish \n1Z \tAny other white ethnic background \n2A \tAny mixed or multiple ethnic groups \n3F \tPakistani, Pakistani Scottish or Pakistani British \n3G \tIndian, Indian Scottish or Indian British \n3H \tBangladeshi, Bangladeshi Scottish or Bangladeshi British \n3J \tChinese, Chinese Scottish or Chinese British \n3Z \tOther Asian \n4D \tAfrican, African Scottish or African British \n4E \tCaribbean, Caribbean Scottish or Caribbean British \n4F \tBlack, Black Scottish or Black British \n4Z \tOther African, Caribbean or Black \n5B \tArab \n5X \tOther Ethnic Group \n98 \tRefused/not provided by the patient \n\t99 \tNot known \n \n \n-\tFrom 1.10.2010 to 30.9.2011 Scottish incidence.  Ethnic Group 3 options only \nFurther changes have been made following a review of ethnicity recording in the 2011 Scottish Census. \n \n-\tFrom 1.10.2011 to 31.3.2012 Scottish incidence.  Ethnic Group 3 options OR Ethnic Group 4 options \n \nEthnic Group 4 \nCode \tDescription \n1A \tWhite-Scottish \n1B \tWhite- Other British \n1C \tIrish \n1K \tGypsy/Traveller \nIL \tPolish \n1Z \tAny other white ethnic background \n2A \tAny mixed or multiple ethnic groups \n3F \tPakistani, Pakistani Scottish or Pakistani British \n3G \tIndian, Indian Scottish or Indian British \n3H \tBangladeshi, Bangladeshi Scottish or Bangladeshi British \n3J \tChinese, Chinese Scottish or Chinese British \n3Z \tOther Asian, Asian Scottish or Asian British \n4D \tAfrican, African Scottish or African British \n4Y \tOther African \n5C \tCaribbean, Caribbean Scottish or Caribbean British \n5D \tBlack, Black Scottish or Black British \n5B \tArab \n5Y \tOther Caribbean or Black \n6A \tArab, Arab Scottish or Arab British \n6Z \tOther Ethnic Group \n98 \tRefused/not provided by the patient \n99 \tNot known \n- From 1.4.2012 Scottish incidence.  Ethnic Group 4 options only", "name": "Ethnic Group", "type": "PrimitiveType"}, {"id": "", "description": "A unique number which will enable the unequivocal identification of individual cancer patients. It is a sequential number allocated by the computer system SOCRATES (For historical data it will result from person-based linkage). It uniquely identifies each person depending on person-based linkage and is subject to change if linkage is reviewed.", "name": "Person Identifier", "type": "PrimitiveType"}, {"id": "", "description": "Latest Surname from the last registration completed (if no previous registrations then name used for provisional notification).", "name": "Latest Surname", "type": "PrimitiveType"}, {"id": "", "description": "All surnames by which this person has been known. This includes maiden names, aliases or differences in spelling.", "name": "All Surnames", "type": "PrimitiveType"}, {"id": "", "description": "Living Status of Patient. Options:  \nCode \tDescription \n1 \tAlive \n2 \tDead \n3 \tMoved out of Scotland \n6 \tPresumed deceased \n9 \tNot Known", "name": "Vital Status", "type": "PrimitiveType"}, {"id": "", "description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x9", "name": "Cause of Death 4", "type": "PrimitiveType"}, {"id": "", "description": "Latest forename from the last registration completed.", "name": "Latest Forename", "type": "PrimitiveType"}, {"id": "", "description": "Date of leaving Scotland (or UK) may be entered by the Cancer Information Officer (CIO) or obtained through nationwide NHSCR linkages.", "name": "Embarkation Date", "type": "PrimitiveType"}, {"id": "", "description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x12", "name": "Cause of Death 7", "type": "PrimitiveType"}, {"id": "", "description": "Pre-CHI is a tick box which can be used to break/remove bad UPI linkages.", "name": "Pre-CHI", "type": "PrimitiveType"}, {"id": "", "description": "This should be ticked to indicate that a patient has died out with Scotland and we have been notified by another Cancer Registry. Death will not be notified through the NRS linkage. This field may explain discrepancy between SOCRATES and ISD warehouse data. This tick box was introduced in the redeveloped SOCRATES.", "name": "OOS (Out of Scotland)", "type": "PrimitiveType"}, {"id": "", "description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x11", "name": "Cause of Death 6", "type": "PrimitiveType"}, {"id": "", "description": "Primary Cause of death. Obtained through NRS linkage and are be coded in ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Registry receives death notifications from various sources - NHSCR, CIO's directly view hospital systems, CHI, other cancer registries, genetic clinics and NRS.", "name": "Cause of Death 1", "type": "PrimitiveType"}, {"id": "", "description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x10", "name": "Cause of Death 5", "type": "PrimitiveType"}, {"id": "", "description": "Not validated but used to record information on the person not provided elsewhere.", "name": "Person Comments", "type": "PrimitiveType"}, {"id": "", "description": "Sex (Gender) of the patient. The persons state of being Male or Female. For those who have under gone gender re-assignment there may be a mismatch recorded between sex and ICD10 code.   Options:\nCode Description\n0 Not Known (i.e. indeterminate sex, includes intersex)\n1 Male\n2 Female\n9 Not Specified (includes not states by patient, or not recorded)", "name": "Sex (Gender)", "type": "PrimitiveType"}, {"id": "", "description": "A Unique Patient Identifier (UPI) was determined to be the CHI number which was most current at the time the indexes were linked ie. The record with the latest date of acceptance on a GP record.  10 digit number consists of 6-digit DOB (DDMMYY) followed by 4 check digits (9th digit denotes sex. 1,3,5,7 or 9 =male, 2,4,6,8 or 0 =female). This field is automatically populated by ascertaining the derived UPI by linking the CHI number held within the Registration Diagnosis screen directly to the CHI database. The Socrates system is also automatically CHI seeded during production run linkage.", "name": "Derived UPI (P_DERIVED_UPI)", "type": "PrimitiveType"}, {"id": "", "description": "Date of patient\u2019s death may be entered by the Cancer Information Officer (CIO) or obtained through linkage to the National Records of Scotland (NRS). The Cancer Registry receives death notifications from various sources - NHSCR, CIO's directly view hospital systems, CHI, other cancer registries, genetic clinics and NRS. Format DD-MMM-YYYY.", "name": "Date of Death", "type": "PrimitiveType"}, {"id": "", "description": "Secondary Cause of death x 3 indicates other causes of death. Obtained through NRS linkage and are coded ICD9 until 31.12.1999 (date of death). Deaths from 1.1.2000 are coded in ICD10. The Cancer Information Officer (CIO) cannot fill this field in. \nFrom 01.01.2013 Cause of death was increased to x7", "name": "Cause of Death 2", "type": "PrimitiveType"}]}, {"id": "", "description": "STAGE DETAILS (Tumour Level)", "name": "STAGE DETAILS", "dataElementsCount": 13, "dataElements": [{"id": "", "description": "FIGO Stage will be collected for malignant tumours of the ovary (ICD10 C56*) with a Scottish incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014  \nSee also FIGO stage before surgery. Options are the same for before or after surgery", "name": "FIGO StageAfter Surgery (Ovary only)", "type": "PrimitiveType"}, {"id": "", "description": "FIGO Stage will be collected for malignant tumours of the Peritoneum (ICD10 C48*) with an incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014  \nSee also FIGO stage after surgery. Options are the same for before or after surgery \n \n \nCode \tDescription \n1 \tTumour confined to the Ovaries (one or both) or fallopian tube(s)  \n1a \tTumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings \n1b \tTumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings  \n1c \tTumour involves 1 or both ovaries or fallopian tubes \n1c1 \tTumour involves 1 or both ovaries or fallopian tubes with surgical spill \n1c2 \tTumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface \n1c3 \tTumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal fluid \n2 \tTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis \n2a \tExtension and/or implant on uterus and/or Fallopian tubes or ovaries \n2b \tExtension to other pelvic intraperitoneal tissues including bowel within the pelvis \n3 \tTumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes \n3a \tPositive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) \n3a1 \tPositive retroperitoneal lymph nodes only \n3a1i \tPositive retroperitoneal lymph node metastases ? 10 mm \n3a1ii \tPositive retroperitoneal lymph node metastases Metastasis > 10 mm \n\t3a2 \t \tMicroscopic, extrapelvic (above the brim) peritoneal involvement \u00b1 positive retroperitoneal lymph nodes including bowel movement \n3b \tMacroscopic, extrapelvic, peritoneal metastasis ? 2 cm \u00b1 positive  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. \n3c \tMacroscopic, extrapelvic, peritoneal metastasis >2 cm \u00b1 positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement \n4 \tDistant metastasis excluding peritoneal metastasis \n4a \tPleural effusion with positive cytology \n4b \tHepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside  of the abdominal cavity) \n9 \tNot known", "name": "Before Surgery (Peritoneum)", "type": "PrimitiveType"}, {"id": "", "description": "FIGO Stage indicates the extent of spread of the invasive primary tumour for cervix at diagnosis in terms of the pathological and/or clinical findings for Socrates. FIGO stage has been collected for malignant tumours of the cervix (ICD10 C53*) with a Scottish incidence  date from 1.1.1997 onwards.  \nThis is a new field to record stage before surgery if possible, and will be collected for all malignant tumours of the cervix (C53*) from 1.1.2005. \nSee also FIGO stage after surgery. Options are the same for before or after surgery. \n \nOptions for cervix:  \nCode \tDescription \n1 \tTumour strictly confined to cervix (extension to the corpus uteri should be disregarded) \n2 \tTumour extends beyond the cervix/uterus but not as far as pelvic wall or lower third of the vagina \n3 \tTumour extends to the pelvic wall or lower third of the vagina (includes all cases with hydronephrosis or non-functioning kidney or both) \n4 \tTumour has invaded or spread beyond the true pelvis, bone, or has clinically involved the mucosa (lining) of the bladder or rectum (bullous oedema as such does not permit a case to be allotted to stage IV) \n9 \tNot Known \nFIGO Stage classification change and from 1.1.2014. See also FIGO stage after surgery. Options are the same for before or after surgery. Options: \nCode \tDescription \n1 \tThe carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded). \n1a \tInvasive carcinoma which can be diagnosed only by microscopy. All macroscopically visible lesions - even with superficial invasion - are allotted to Stage Ib carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.0 mm and horizontal extension of not > 7.0 mm. Depth of invasion should not be > 5.0 mm taken from the base of the epithelium of the original tissue - superficial or glandular. The involvement of vascular spaces should not change the stage allotment. \n1a1 \tMeasured stromal invasion of not > 3.0 mm in depth and extension of not > 7.0 mm. \n1a2 \tMeasured stromal invasion of > 3.0 mm and not > 5.0 mm with an extension of not > 7.0 mm. \n1b \tClinically visible lesions limited to the cervix uteri or preclinical cancers greater than Stage IA. \n1b1 \tClinically visible lesions not > 4.0 cm. \n1b2 \tClinically visible lesions > 4.0 cm. \n2 \tCervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina. \n2a \tNo obvious parametrial involvement. \n2a1 \tClinically visible lesion <=4.0 cm in greatest dimension \n2a2 \tClinically visible lesion >4.0 cm in greatest dimension \n2b \tObvious parametrial involvement. \n3 \tThe carcinoma has extended to the pelvic wall. On rectal examination, there is no cancer-free space between the tumour and the pelvic wall. The tumour involves the lower-third of the vagina. All cases with hydronephrosis or non-functioning kidney are included, unless they are known to be due to other causes. \n3a \tTumour involves lower-third of the vagina, with no extension to the pelvic wall. \n3b \tExtension to the pelvic wall and/or hydronephrosis or non-functioning kidney \n4 \tThe carcinoma has extended beyond the true pelvis, or has involved (biopsy-proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to Stage IV. \n4a \tSpread of the growth to adjacent organs. \n4b \tSpread to distant organs. \n9 \tNot known", "name": "FIGO Stage \u2013 Before Surgery (Cervix only)", "type": "PrimitiveType"}, {"id": "", "description": "FIGO Stage will be collected for malignant tumours of the Corpus Uteri (ICD10 C54*) with a Scottish incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014  \nSee also FIGO stage before surgery. Options are the same for before or after surgery", "name": "FIGO StageAfter Surgery (Corpus Uteri only)", "type": "PrimitiveType"}, {"id": "", "description": "Stage (Colorectal) indicates the extent of spread of the invasive tumour at diagnosis in terms of the pathological and/or clinical findings for Socrates. Extent of Primary tumour for Colorectal cancer - \nDukes\u2019 staging is primarily based on histological findings.  Dukes\u2019 Staging Classification Options: \n \nCode \tDescription \nA \tTumour limited to muscularis propria (muscle coat), regional lymph nodes negative \nB \tTumour invades through muscularis propria into serosa/subserosa or through peritoneum but regional lymph nodes negative \nC1 \tRegional lymph nodes positive but apical node negative \nC2 \tRegional lymph nodes positive, apical lymph node positive \nD \tDistant metastases (e.g. liver) \n9 \tNot Known \nNote: Dukes\u2019 stage D was not included in the original Dukes\u2019 classification \nNote:  Regional lymph nodes are the pericolic and perirectal and those located along the ileocolic, right colic, middle colic, left colic, inferior mesenteric and superior rectal (haemorrhoidal) arteries \nThis field is collected for all registrations with a Scottish incidence date from 1.1.1997 onwards for all malignant colorectal (ICD10 C18 \u2013 C20) and anal (ICD10 C21) tumours.", "name": "Dukes\u2019 Stage (Colorectal only)", "type": "PrimitiveType"}, {"id": "", "description": "FIGO Stage will be collected for malignant tumours of the Fallopian Tube (ICD10 C57*) with a Scottish incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014  \nSee also FIGO stage after surgery. Options are the same for before or after surgery \n \n \n\tCode \tDescription \n\t1 \tTumour confined to the Ovaries (one or both) or fallopian tube(s)  \n\t1a \tTumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings \n\t1b \tTumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings  \n\t1c \tTumour involves 1 or both ovaries or fallopian tubes \n\t1c1 \tTumour involves 1 or both ovaries or fallopian tubes with surgical spill \n\t1c2 \tTumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface \n\t1c3 \tTumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal fluid \n\t2 \tTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis \n\t2a \tExtension and/or implant on uterus and/or Fallopian tubes or ovaries \n\t2b \tExtension to other pelvic intraperitoneal tissues including bowel within the pelvis \n\t3 \tTumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes \n\t3a \tPositive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) \n\t3a1 \tPositive retroperitoneal lymph nodes only \n\t3a1i \tPositive retroperitoneal lymph node metastases ? 10 mm \n\t3a1ii \tPositive retroperitoneal lymph node metastases Metastasis > 10 mm \n\t\t3a2 \t \tMicroscopic, extrapelvic (above the brim) peritoneal involvement \u00b1 positive retroperitoneal lymph nodes including bowel movement \n\t3b \tMacroscopic, extrapelvic, peritoneal metastasis ? 2 cm \u00b1 positive  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. \n\t3c \tMacroscopic, extrapelvic, peritoneal metastasis >2 cm \u00b1 positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement \n\t4 \tDistant metastasis excluding peritoneal metastasis \n\t4a \tPleural effusion with positive cytology \n4b \tHepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside  of the abdominal cavity) \n9 \tNot known", "name": "FIGO Stage-Before Surgery (Fallopian Tube)", "type": "PrimitiveType"}, {"id": "", "description": "Options: \nCode \tDescription \n1 \tLocalised \n2 \tRegional spread    \n3 \tDistant metastasis   \n4 \tNot Known \n \nThis field will be collected for all malignant lung tumours (C34*) registered with a Scottish incidence date from 1.1.2005 to 31.12.2012", "name": "Clinical extent of disease (Lung only)", "type": "PrimitiveType"}, {"id": "", "description": "FIGO Stage will be collected for malignant tumours of the Fallopian Tube (ICD10 C57*) with a Scottish incidence date from 1.1.2005 onwards. \nFIGO Stage classification change from 1.1.2014  \nSee also FIGO stage before surgery. Options are the same for before or after surgery", "name": "FIGO StageAfter Surgery (Fallopian Tube)", "type": "PrimitiveType"}, {"id": "", "description": "FIGO Stage indicates the extent of spread of the invasive primary tumour for cervix at diagnosis in terms of the pathological and/or clinical findings for Socrates. \nPreviously this field was known as FIGO Stage, and was collected for all malignant tumours of the cervix (ICD10 C53*) from 1.1.1997 onwards. All tumours recorded with a FIGO stage from 1.1.1997 to 31.12.2004 will exist on the SOCRATES database with a FIGO stage in the After Surgery field. \nFIGO Stage classification change from 1.1.2014  \nSee also FIGO stage before surgery. Options are the same for before or after surgery", "name": "FIGO StageAfter Surgery (Cervix only)", "type": "PrimitiveType"}, {"id": "", "description": "FIGO Stage indicates the extent of spread of the invasive primary tumour for Corpus Uteri (C54#) at diagnosis in terms of the pathological and/or clinical findings for Socrates. \nFIGO Stage classification change from 1.1.2014 to include Corpus Uteri \nSee also FIGO stage after surgery. Options are the same for before or after surgery. \n \nCode \tDescription \n1 \tTumour contained to corpus uteri \n1a \tNo or less than half myometrial invasion \n1b \tInvasion equal to or more than half of the myometrium \n2 \tTumour invades the cervical stroma but does not extend beyond the uterus \n3 \tLocal and/or regional spread of tumour \n3a \tTumour invades the serosa of the corpus uteri and/or adnexas \n3b \tVaginal and/or parametrial involvement \n3c \tMetastases to pelvis and/or para-aortic lymph nodes \n3c1 \tPositive pelvic nodes \n3c2 \tPositive para-aortic lymph nodes with or without positive pelvic lymph nodes \n4 \tTumour invades into bladder and/or bowel mucosa and/or distant metastasis \n4a \tTumour invasion bladder and/or bowel \n4b \tDistant metastases including intra-abdominal and/or inguinal lymph nodes \n9 \tNot known", "name": "FIGO Stage-\nBefore Surgery (Corpus Uteri only)", "type": "PrimitiveType"}, {"id": "", "description": "This staging group indicates the extent of disease progression of invasive testicular tumours.  (ICD10 C62*) with an incident date from 1.1.2015.\n \nOptions are: \nCode \nI \nIA \nIB \nII \nIIA \nIIB \nIIC \nIII \nIIIA \nIIIB \nIIIC \nIS \nNK", "name": "Staging Group Testicular", "type": "PrimitiveType"}, {"id": "", "description": "FIGO Stage will be collected for malignant tumours of the ovary (ICD10 C56*) with a Scottish incidence date from 1.1.2005 onwards. As with cervix, this is a new field. \nSee also FIGO stage after surgery. Options are the same for before or after surgery. \n \nCode \tDescription \n1 \tTumour confined to the Ovaries (one or both) or fallopian tube(s)  \n1a \tTumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings  \n1b \tTumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings  \n1c \tTumour involves 1 or both ovaries or fallopian tubes  \n \n1C1 \tTumour involves 1 or both ovaries or fallopian tubes with surgical spill  \n1C2 \tTumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface  \n1C3 \tTumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritone \nTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis  al fluid  \n2 \tTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis  \n2a \tExtension and/or implant on uterus and/or Fallopian tubes or ovaries  \n2b \tExtension to other pelvic intraperitoneal tissues including bowel within the pelvis  \n3 \tTumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes  \n3A \tPositive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis)  \n3A1 \tPositive retroperitoneal lymph nodes only  \n3A1i \tPositive retroperitoneal lymph node metastases ? 10 mm  \n3A1ii \tPositive retroperitoneal lymph node metastases Metastasis > 10 mm  \n3A2 \tMicroscopic, extrapelvic (above the brim) peritoneal involvement \u00b1 positive retroperitoneal lymph nodes including bowel movement  \n3B \tMacroscopic, extrapelvic, peritoneal metastasis ? 2 cm \u00b1 positive  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen.  \n3C \tMacroscopic, extrapelvic, peritoneal metastasis >2 cm \u00b1 positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement  \n4 \tDistant metastasis excluding peritoneal metastasis \n4A \tPleural effusion with positive cytology  \n4B \tHepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside  of the abdominal cavity)  \n9 \tNot Known \n \nFIGO Stage classification change and from 1.1.2014 the options are: \nSee also FIGO stage after surgery. Options are the same for before or after surgery. \n \n \n\tCode \tDescription \n1 \tTumour confined to the Ovaries (one or both) or fallopian tube(s)  \n1a \tTumour limited to 1 ovary, capsule intact, no tumour on ovarian or fallopian tube surface, negative washings \n1b \tTumour involves both ovaries or fallopian tubes, capsule intact, no tumour on surface, negative washings  \n1c \tTumour involves 1 or both ovaries or fallopian tubes with the following features: \n1c1 \tTumour involves 1 or both ovaries or fallopian tubes with surgical spill \n1c2 \tTumour involves 1 or both ovaries or fallopian tubes with ovarian capsule rupture prior to surgery or tumour on ovarian or tube surface \n1c3 \tTumour involves 1 or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal fluid \n2 \tTumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below the pelvic brim) or primary peritoneal cancer in the pelvis \n2a \tExtension and/or implant on uterus and/or Fallopian tubes or ovaries \n2b \tExtension to other pelvic intraperitoneal tissues including bowel within the pelvis \n3 \tTumour involves 1 or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes \n3a \tPositive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis) \n3a1 \tPositive retroperitoneal lymph nodes only \n3a1i \tPositive retroperitoneal lymph node metastases ? 10 mm \n3a1ii \tPositive retroperitoneal lymph node metastases Metastasis > 10 mm \n\t3a2 \t \tMicroscopic, extrapelvic (above the brim) peritoneal involvement \u00b1 positive retroperitoneal lymph nodes including bowel movement \n3b \tMacroscopic, extrapelvic, peritoneal metastasis ? 2 cm \u00b1 positive  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. \n3c \tMacroscopic, extrapelvic, peritoneal metastasis >2 cm \u00b1 positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen but not parenchymal involvement \n4 \tDistant metastasis excluding peritoneal metastasis \n4a \tPleural effusion with positive cytology \n4b \tHepatic and/or splenic parenchymal metastasis, metastasis to extra - abdominal organs (including inguinal lymph nodes and lymph nodes outside  of the abdominal cavity) \n9 \tNot known", "name": "FIGO Stage \u2013 Before Surgery (Ovary only)", "type": "PrimitiveType"}, {"id": "", "description": "Please refer to staging document \nAJCC \u2013 American Joint Committee on Cancer indicates the extent of disease progression of invasive melanoma tumours. \nAJCC is collected for malignant melanomas of the skin (ICD10 C43*) with an incident date from \n1.1.2015 \nOptions for AJCC version 7 are: \nCode \nIA \nIB \nIIA \nIIB \nIIC \nIII \nIIIA \nIIIB \nIIIC \nIV \nX \n \nFrom 01.01.2018 the following options apply for AJCC version 8: \n \n \tCode \n\tIA \n\tIB \n\tIIA \n\tIIB \n\tIIC \n\tIII \n\tIIIA \n\tIIIB \n\tIIIC \n\tIIID \n\tIV \n\tX", "name": "TNM AJCC (Melanoma)", "type": "PrimitiveType"}]}, {"id": "", "description": "SYSTEM ADMINISTRATION DATA (Person & tumour level)", "name": "SYSTEM ADMINISTRATION DATA", "dataElementsCount": 16, "dataElements": [{"id": "", "description": "Tick box to indicate that a registration has been considered to be an independent primary tumour, regardless of the existence of other registrations with a similar diagnosis.", "name": "Independent Primary Tumour", "type": "PrimitiveType"}, {"id": "", "description": "Indicates if the record is a provisional registration, a validated / confirmed registration, or a previously deleted registration", "name": "Confirmed,Provisional or Deleted", "type": "PrimitiveType"}, {"id": "", "description": "If transferred to another hospital batch this field will indicate where the provisional registration was last transferred from", "name": "Previous Hospital", "type": "PrimitiveType"}, {"id": "", "description": "ICDO(3) - International Classification of Diseases for Oncology (3rd revision). Tumour type indicates the morphology (histology) of the tumour and comprises the first four digits of the ICDO(3) morphology code and a fifth digit which denotes behavior. This is recorded for haematological transformations  which have occurred since 01.01.2013", "name": "Transformation ICDO3", "type": "PrimitiveType"}, {"id": "", "description": "\u2018Berg\u2019 grouping for similar morphological families", "name": "Berg Morphology", "type": "PrimitiveType"}, {"id": "", "description": "Derived from Quality Checks. Indicates date and description of check. Options: \nCode \tDescription \n10 \tNon-specific morphology \n11 \t18QA \n12 \tUnder 25 no treatment \n13 \tNK Staging \n14 \tScheduled QA", "name": "Checks", "type": "PrimitiveType"}, {"id": "", "description": "Hospital code is allocated by the system according to the data source where it is presumed the medical records with the most information on the patient will be available. Once this code has been allocated the CRO(s) who work with that institution or area will be able see these provisional records in their batch. This code will usually be associated with the provisional notification before registration, and may not correspond to the registered hospital of diagnosis & Case Ref. no.", "name": "Hospital  Code", "type": "PrimitiveType"}, {"id": "", "description": "Indicates that a particular quality check has been completed for a particular record. There are a growing number of options due to the development of a more comprehensive quality assurance programme in Cancer Registration.", "name": "Quality Checks", "type": "PrimitiveType"}, {"id": "", "description": "The initial date the provisional registration was inserted into the hospital batch for the Cancer Information", "name": "Date into Batch", "type": "PrimitiveType"}, {"id": "", "description": "Officer (CIO) to work with SOCRATES Grouping for similar tumour site families", "name": "Subcluster Code", "type": "PrimitiveType"}, {"id": "", "description": "Indicates that a haematological transformation has occurred recorded for Scottish incidence year 2013 onwards", "name": "Transformation Date", "type": "PrimitiveType"}, {"id": "", "description": "Date the record was last updated", "name": "Last Updated Date", "type": "PrimitiveType"}, {"id": "", "description": "Code denoting the last Cancer Information Officer (CIO) who made an amendment to the registration", "name": "Last Updated By", "type": "PrimitiveType"}, {"id": "", "description": "Latest comment to be added regarding the tumour. There is a List Notes button available to view previous notes.", "name": "Latest Note", "type": "PrimitiveType"}, {"id": "", "description": "Date provisional registration was last transferred", "name": "Transfer Date", "type": "PrimitiveType"}, {"id": "", "description": "ICD10 \u2013 International Classification of Diseases (10th revision) recorded for haematological transformations which have occurred since 01.01.2013", "name": "Transformation ICD10", "type": "PrimitiveType"}]}, {"id": "", "description": "Source Data", "name": "Source Data", "dataElementsCount": 59, "dataElements": [{"id": "", "description": "As defined previously", "name": "Forenames", "type": "PrimitiveType"}, {"id": "", "description": "Indicates the creation rule decision (NEW \u2013 new tumour, MP1 \u2013 different at sub cluster code etc)", "name": "Create Point", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "Surname", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "Sex", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously.", "name": "Incidence Date", "type": "PrimitiveType"}, {"id": "", "description": "Site code used for notifications before any conversions.", "name": "Unconverted Site 8", "type": "PrimitiveType"}, {"id": "", "description": "Socrates link weight", "name": "SOC link", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "Date Of Birth", "type": "PrimitiveType"}, {"id": "", "description": "Unique number generated for CDP (Cancer Data Processing) for all notifications.", "name": "Accession Number", "type": "PrimitiveType"}, {"id": "", "description": "Additional information from the Pathology text i.e. site of tumour/excision/substance", "name": "Site \u2013 short desc", "type": "PrimitiveType"}, {"id": "", "description": "Record Type of data. Options: \n \nCode \tDescription \n00 \tSMR00 \n10 \tSMR01 \n11 \tPrivate Hospital \n2% \tPathology \n3% \tRadiotherapy \n51 \tOncology \n52 \tCommunity Prescribing \n62 \tCervix Screening \n70 \tChemocare \n75 \tCancer Waiting Times \n90 \tNRS death notification - quarterly \n98 \tNRS death notification - annual", "name": "Type", "type": "PrimitiveType"}, {"id": "", "description": "Local ref. no such as lab no", "name": "Local Patient ID", "type": "PrimitiveType"}, {"id": "", "description": "Hospital code converted from text input if pathology data or 3 digit code if WGH radiotherapy data", "name": "Hospital Converted", "type": "PrimitiveType"}, {"id": "", "description": "Operation or procedure code used for notifications from SMR01.", "name": "Procedures - OP2", "type": "PrimitiveType"}, {"id": "", "description": "GP Practice code", "name": "GP Code", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "Address", "type": "PrimitiveType"}, {"id": "", "description": "Operation or procedure code used for notifications from SMR01.", "name": "Procedures \u2013 OP3", "type": "PrimitiveType"}, {"id": "", "description": "Operation or procedure code used for notifications from SMR01.", "name": "Procedures \u2013 OP7", "type": "PrimitiveType"}, {"id": "", "description": "Staging information if available", "name": "Stage", "type": "PrimitiveType"}, {"id": "", "description": "Operation or procedure code used for notifications from SMR01.", "name": "Procedures \u2013 OP4", "type": "PrimitiveType"}, {"id": "", "description": "Site code used for notifications before any conversions.", "name": "Unconverted Site 7", "type": "PrimitiveType"}, {"id": "", "description": "Type code used for notifications before any conversions.", "name": "Unconverted Morphology", "type": "PrimitiveType"}, {"id": "", "description": "(SMR01) Hospital admission date", "name": "Date of Admission", "type": "PrimitiveType"}, {"id": "", "description": "Site code used for notifications before any conversions.", "name": "Unconverted Site 2", "type": "PrimitiveType"}, {"id": "", "description": "Subcluster Code grouping of cancer site codes - used for the elimination of similar notifications.", "name": "Sub Code", "type": "PrimitiveType"}, {"id": "", "description": "Site code used for notifications before any conversions.", "name": "Unconverted Site 4", "type": "PrimitiveType"}, {"id": "", "description": "Consultant code,  Clinician certifying death on GRO records, Hospital areas on Pathology reports etc", "name": "Sent By", "type": "PrimitiveType"}, {"id": "", "description": "Converted to ICD-10 code from SNOMED and ICD-9 codes", "name": "ICD-10 Conv. Site", "type": "PrimitiveType"}, {"id": "", "description": "Site code used for notifications before any conversions.", "name": "Unconverted Site 3", "type": "PrimitiveType"}, {"id": "", "description": "Converted from SNOP codes (WGH radiotherapy) or eg M-80003 to 80003", "name": "Converted Morphology", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "CHI", "type": "PrimitiveType"}, {"id": "", "description": "Operation or procedure code used for notifications from SMR01.", "name": "Procedures \u2013 OP5", "type": "PrimitiveType"}, {"id": "", "description": "Original code or text received from source data.", "name": "Hospital Unconverted", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "Previous Name", "type": "PrimitiveType"}, {"id": "", "description": "Site code used for notifications before any conversions.", "name": "Unconverted Site 5", "type": "PrimitiveType"}, {"id": "", "description": "Operation or procedure code used for notifications from SMR01.", "name": "Procedures - OP1", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "Ethnic Group", "type": "PrimitiveType"}, {"id": "", "description": "Production run load number. Indicates when source data record was processed", "name": "Load num", "type": "PrimitiveType"}, {"id": "", "description": "Describes the outcome of the addition of a source data record. Options: \n \nCode \tDescription \nD \tNon-cancer death for unknown person \nE \tError has been caused by this record   \nJ \tDuplicate data   \nM \tData rejected by multiple primary rules   \nP \tData used to create provisional record   \nS \tData rejected by secondary rules   \nX \tSupplementary data added to an open provisional record", "name": "New Data", "type": "PrimitiveType"}, {"id": "", "description": "Full pathology text.", "name": "Pathology", "type": "PrimitiveType"}, {"id": "", "description": "Operation or procedure code used for notifications from SMR01.", "name": "Procedures \u2013 OP6", "type": "PrimitiveType"}, {"id": "", "description": "Tumour size if available", "name": "Size", "type": "PrimitiveType"}, {"id": "", "description": "Specialty for SMR01 data & Request Type for pathology data e.g. A for autopsy", "name": "Specialty or Req Type", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "Postcode", "type": "PrimitiveType"}, {"id": "", "description": "Main source of notification e.g. GRO-S, SMR01 or source location code of hospital of pathology/radiotherapy", "name": "Data Source", "type": "PrimitiveType"}, {"id": "", "description": "Site code used for notifications before any conversions.", "name": "Unconverted Site 6", "type": "PrimitiveType"}, {"id": "", "description": "Additional information from the Pathology text i.e. type of excision From Community Prescribing data this displays the prescribed drug.", "name": "Site \u2013 long desc", "type": "PrimitiveType"}, {"id": "", "description": "TNM information if available", "name": "TNM", "type": "PrimitiveType"}, {"id": "", "description": "Not used", "name": "Int link", "type": "PrimitiveType"}, {"id": "", "description": "Site code used for notifications before any conversions.", "name": "Unconverted Site 1", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "Marital Status", "type": "PrimitiveType"}, {"id": "", "description": "Berg morphology type grouping code used to eliminate multiple primary/duplicate notifications", "name": "Berg Group", "type": "PrimitiveType"}, {"id": "", "description": "Morphology description", "name": "Morphology desc", "type": "PrimitiveType"}, {"id": "", "description": "Date of death if available at source", "name": "Source DOD", "type": "PrimitiveType"}, {"id": "", "description": "Ward number if available", "name": "Ward", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "NHS Number", "type": "PrimitiveType"}, {"id": "", "description": "Operation or procedure code used for notifications from SMR01.", "name": "Procedures \u2013 OP8", "type": "PrimitiveType"}, {"id": "", "description": "(Hospital Patient ID) As defined previously", "name": "Case Ref No", "type": "PrimitiveType"}, {"id": "", "description": "As defined previously", "name": "Derived CHI", "type": "PrimitiveType"}]}]